Treating malignant melanoma with lower doses of approved immunotherapy appears to result in improved results, while also reducing side effects. Investigators from the Karolinska Institutet in Stockholm, Sweden… read more.
Some blood pressure medications can make the skin extra prone to sunburn. A registry study from Lund University in Sweden shows a possible increased risk of basal cell… read more.
Adult acne is more common than often assumed. According to research from the University of Oulu, around 31 per cent of 35-year-old Finnish women have acne on the… read more.
Incyte announced new data from the Phase IIIb TRuE-AD4 study evaluating the efficacy and safety of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who had… read more.
NICE (UK): Delgocitinib can be used, within its marketing authorisation, as an option to treat moderate to severe chronic hand eczema in adults when topical corticosteroids have not… read more.
Pelthos Therapeutics Inc. announced it has acquired the U.S. marketing rights to Xepi (ozenoxacin) Cream, 1%, from Biofrontera Inc. and Ferrer Internacional S.A. (the Xepi is a non-fluorinated… read more.
Journey Medical Corporation announced that the FDA has approved Emrosi(minocycline hydrochloride extended release capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Tremfya (guselkumab). The marketing… read more.
Australia needs to be innovative when it comes to skin cancer detection by embracing a nurse-led model that could save thousands of lives in the long run, according… read more.
Arcutis Biotherapeutics, Inc. announced that the FDA has approved the supplemental new drug application (sNDA) for Zoryve (roflumilast) cream 0.05% for the topical treatment of mild to moderate… read more.
Researchers report that patients with psoriasis treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) have achieved a 78% reduced risk of death and a 44% reduced risk of major… read more.
Arcutis Biotherapeutics Inc. announced the submission of a supplemental New Drug Application (sNDA) to the FDA to expand the indication of Zoryve (roflumilast) ) cream 0.3% for the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
